Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study
Authors' conclusion
Our findings are in line with previous reporting, demonstrating that the majority of patients respond to immunosuppressive therapy, and the association of anti-SRP myopathy with more prominent systemic involvement.
Study context
- Population
- All patients with anti-SRP or anti-HMGCR positive myopathy managed at a tertiary neuromuscular centre, 2010–2023
- Participants
- 57 patients
- Exposure
- Anti-SRP vs anti-HMGCR immune-mediated necrotising myopathy (IMNM)
- Anti-SRPn = 15
- Anti-HMGCRn = 42reference
Methodological detailsobservational, single-centre, tertiary neuromuscular centre
- Observational
- Single-centre
- Tertiary neuromuscular centre
Further findings
Age at disease onset
P < 0.001
ILD
Arthritis
Treatment-free remission
Malignancy incidence (overall)
- Overall malignancy incidence
- 12.3%
- Low in both subgroups
Anti-HMGCR: correlation of antibody titres with CK and troponin T
- Titres vs CK, r (p<0.001)
- 0.692
- Titres vs troponin T, r (p=0.014)
- 0.476
Original publication
Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study. Clin Exp Rheumatol. Published 21 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →